Dr. Herbst on the Emergence of Immunotherapy in Cancer

Roy S. Herbst, MD, PhD
Published: Wednesday, Jun 05, 2013

The 2013 ASCO Annual Meeting highlighted the emergence of immunotherapy as a treatment in multiple types of cancer, says Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut.

Herbst presented data on the antibody MPDL3280A that targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including non-small cell lung cancer. Additionally, Herbst adds, the safety profile was acceptable, with only a few patients experiencing immune related adverse events.

Immunotherapeutic approaches are very promising in the treatment of NSCLC, Herbst points out. This is further highlighted by trials exploring the agent nivolumab, which targets PD-1. The combination of data from the trials exploring PD-1 and PD-L1 demonstrates the emergence of an effective new avenue in the treatment of patients with lung cancer, Herbst believes.

The 2013 ASCO Annual Meeting highlighted the emergence of immunotherapy as a treatment in multiple types of cancer, says Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut.

Herbst presented data on the antibody MPDL3280A that targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including non-small cell lung cancer. Additionally, Herbst adds, the safety profile was acceptable, with only a few patients experiencing immune related adverse events.

Immunotherapeutic approaches are very promising in the treatment of NSCLC, Herbst points out. This is further highlighted by trials exploring the agent nivolumab, which targets PD-1. The combination of data from the trials exploring PD-1 and PD-L1 demonstrates the emergence of an effective new avenue in the treatment of patients with lung cancer, Herbst believes.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x